

# ATC1 GROUP DISCOUNT DISTRIBUTION ANALYSIS OF ORIGINAL MEDICINES WHICH HAS NO GENERICS IN TURKEY

E. Kagan Atikeler<sup>1</sup>, Fatma Betul Yenilmez<sup>1</sup>, Esin Tuna<sup>1</sup>, Guvenc Kockaya<sup>2</sup>

<sup>1</sup>Hacettepe University, Social Sciences, Hacettepe Beytepe Campus, Ankara, Turkey, <sup>2</sup>Health Economics and Policy Association, Ankara, Turkey

## Objectives

Pharmaceutical industry continues to grow and drug prices are a burden for countries. Reference price system is assumed that such a practice concerning medicines will lead to a decrease in medicine expenditures as medicine prices decrease. The purpose of this analysis is to determine the distribution of the discount of original medicines in ATC groups from the reimbursement agency perspective in Turkey.

## Methodology

In the analysis, “Detailed Price List” data published on the website of the Ministry of Health’s Turkish Medicines and Medical Devices Agency (TMMDA) and “Annex 4-A Funded Medicines List” data published by Social Security Institution (SSI) were used. The lists were merged using the Excel software and generic medicine including genericized original medicines with different pricing and payment conditions compared to original medicines with no generics and other specific medicines such as blood products, enteral nutrition products, etc. and specific conditions such as medicines with no reimbursement were excluded. The analysis was made with a total of 568 original medicines with no generic. Ex-factory prices were used in the analysis.


## Results

The original drug distribution examination according to ATC1 groups showed that groups B and L had the highest number of original medicines with no generic with 16.55%. The price distribution examination according to ATC1 groups showed that the most expensive original medicines with no generic were in group L with 27.31%. The examination of SSI discount rates according to ATC1 groups showed that original medicines in group S had the highest average discount rate with 46.1%. The ATC1 group with the second highest average discount rate, 41%, was not specified and identified to be original medicines in group M.

## Conclusion

In ATC1 group the original drugs distribution is mostly contains group B and L. The highest-priced original drugs are in ATC1 is in L group that is also expected in terms of the properties of L group. The highest discount rates are in group S however, the lowest price of original drugs are also in S group.

Chart 1. Original Drug Distribution According To ATC1 Groups



## References

1. Arslanhan Memis S., (2013). Fiyat ve Geri Ödeme Politikalarının İlaç Sanayii Üzerine Etkisi, Türkiye Ekonomi Politikaları Araştırma Vakfı Politika Notu. (<http://www.tepav.org.tr/upload/files/1357211706-5>)
2. Atikeler, K., Özcelikay, G., (2014). Türkiye ve Bazı Ülkelerde İlaçta Fiyatlandırma ve Geri Ödeme Sistemlerinin Karşılaştırılması, Yüksek Lisans Tezi, Ankara Üniversitesi Sağlık Bilimleri Enstitüsü, Ankara.
3. Caliskan, Z., (2008). Sağlık Hizmetlerinde Önceliklerin Belirlenmesinde Ekonomik Değerlendirme Yöntemi Olarak Maliyet-Etkilik Analizi, Suleyman Demirel Üniversitesi, İktisadi ve İdari Bilimler Fakültesi Dergisi, (14)2: 311-332.
4. Caliskan, Z., (2009). Referans Fiyat ve İlaç Piyasası, Hacettepe Sağlık İdaresi Dergisi, (11)1: 50-51.
5. Dogan, E., (2014). Türkiye’de İlaçların Fiyatlandırılması Sunumu, Hacettepe Üniversitesi Eczacılık Fakültesi Ders Notu DPT (2006). Sekizinci Bes Yıllık Kalkınma Planı, İlaç Sanayii Özel İhtisas Komisyonu Raporu, Ankara.
6. Gulergun, E., Karakoc, H., Hatipoglu, C., (2013). Sektör Araştırması Raporu, Rekabet Kurumu. (<http://www.rekabet.gov.tr/File/?path=ROOT%2F1%2FDocuments%2FSekt%C3%B6rRaporu%2FIlacrapor.pdf>, Access Date: 22.05.2015)